Cardiovascular concerns are on the rise for people with diabetes, both in terms of acute and chronic complications, and a panel of scientists will discuss potential new therapies to improve diabetes-related cardiovascular residual risk in a morning symposium on Sunday, June 25.
New Treatment Possibilities for Cardiovascular Residual Risk in Diabetes? will address contributing factors, therapeutic targets, and assessment at 8:00 a.m. PT in Room 28. This session also will be available via livestream for registered meeting participants.
Jan Borén, MD, PhD, Professor and Head of the Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Sweden, will discuss two drugs in his lecture, “ANGPTL3 vs. APOC3 as a Therapeutic Target?”
Elevated levels of triglyceride-rich lipoproteins (TRLs) can be linked to residual risk of cardiovascular disease for people with diabetes. Studies indicate that apolipoprotein C-III (APOC3) and angiopoietin-like (ANGPTL) 3 are key regulators of the metabolism of TRLs. Both are now drug targets for reducing atherogenic TRLs and TRL remnants, and clinical trials are ongoing.
“Recent advances in human genetics, together with a large body of epidemiologic and clinical trial results, indicate that the remaining ‘residual’ risk of cardiovascular disease is caused by elevated levels of TRLs and their remnants,” Dr. Borén said. “However, the precise mechanisms involved remain still unclear. Thus, there is an urgent need to better understand the underlying mechanisms and to develop effective treatment strategies to reduce the residual risk in individuals with hypertriglyceridemia.”
Anne Tybjærg-Hansen, MD, DMSc, Chief Physician in the Department of Clinical Biochemistry, Section for Molecular Genetics, Rigshospitalet, Copenhagen University Hospital, Denmark, will discuss whether triglycerides contribute to residual cardiovascular disease risk in diabetes.
Calvin Yeang, MD, PhD, Assistant Professor, University of California San Diego School of Medicine, will address whether there is evidence that Lp(a) is significant in diabetes risk assessment.